0000950170-24-018175.txt : 20240221
0000950170-24-018175.hdr.sgml : 20240221
20240221174522
ACCESSION NUMBER: 0000950170-24-018175
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240218
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KASINGER JAMES R.
CENTRAL INDEX KEY: 0001708172
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 24661317
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS, INC.
STREET 2: 610 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2024-02-18
0001674416
CRISPR Therapeutics AG
CRSP
0001708172
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
false
true
false
false
General Counsel and Secretary
false
Common Shares
2024-02-18
4
M
false
3825
A
59284
D
Common Shares
2024-02-20
4
S
false
1913
79.67
D
57371
D
Restricted Stock Units
2024-02-18
4
M
false
3825
D
Common Shares
3825
7650
D
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
/s/ AJ Silver, attorney-in-fact
2024-02-21